Product Description.:
NVR, IU
tablet , red , oval oblong
Biconvex
Tekturna is an orally active, nonpeptide, potent renin inhibitor. Renin is the enzyme at the beginning of the Renin Angiotensin System (RAS), one of the key regulators of blood pressure. Suppression of the RAS has been shown to treat hypertension and reduce cardiovascular events.
Tekturna is specifically indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. The use of Tekturna with maximal doses of ACE inhibitors has not been adequately studied.
Tekturna is supplied as a 150 mg or 300 mg tablet designed for oral administration. The recommended initial dose of the drug is 150 mg once daily. In patients who do not have adequately controlled blood pressure, the daily dose may be increased to 300 mg.
Side Effects
Adverse events associated with the use of Tekturna may include, but are not limited to, the following
* Hand, face and/or body edema
* Diarrhea
* Abdominal pain
* Dyspepsia
* Gastroesophageal reflux
* Rash
* Elevated uric acid
* Gout
* Renal stones
